 
            IndraLab
Statements
                                      reach
                                
                                  
                                
                                
          
          
                                  "Expert opinionSelective and reversible inhibitors of ubiquitin specific protease 7 : a patent evaluation (WO2013030218) Benedikt M KesslerUniversity of Oxford, Target Discovery Institute, Nuffield Department of Medicine, Oxford, UKThe invention described in this review (WO2013030218) relates to compounds based on the quinazolin-4-one scaffold, their process of preparation and applications to inhibit the ubiquitin specific protease 7 (USP7), a deubiquitinating enzyme (DUB), which is considered a potentially important new drug target for treating cancer and immunological disorders."
          
                              
          
                               
                            
                                      reach
                                
                                  
                                
                                
          
          
                                  "As increased TAL1 oncogenic activity was also evident in the accelerated cell growth observed after CRISPR knock-out of half of the USP7 loci in T-ALL cell lines, we hypothesize that USP7 haploinsufficiency in T-ALL down-regulates the ability of this deubiquitylating enzyme to remove ubiquitin from E-proteins, leads to enhanced TAL1 heterodimer formation, which favors TAL1 mediated thymocyte transformation."
          
                              
          
                               
                            
                                      reach
                                
                                  
                                
                                
          
          
                                  "Taken together, these data suggest that RNF4 is responsible for sustaining DNA replication and repairing damage that occurs in USP7 mutants.Bortezomib depletes the nuclear pool of ubiquitin and impairs K63-linked polyubiquitination of H2AX, a requirement for the recruitment of BRCA1 and RAD51 to DSBs [74], leading to the accumulation of unrepaired breaks [64]."